Becker's Healthcare March 15, 2024
After the FDA questioned the safety of two CAR-T therapies, members of the agency’s Oncologic Drugs Advisory Committee voted unanimously to recommend Carvykti, made by Janssen Biotech, and voted 8-3 in favor for Abecma, from Bristol-Myers Squibb K.K.
Carvykti is now recommended by the panel, for “treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent and who are refractory to lenalidomide,” according to a March 15 news release from Janssen.
“As a physician and researcher committed to advancing patient care, the potential of Carvykti in earlier lines of therapy represents an important therapeutic option for patients with multiple myeloma,” Jordan...
Today's Sponsors
Today's Sponsor